APA (7th ed.) Citation

Sulkowski, M. S., Feld, J. J., Lawitz, E., Felizarta, F., Corregidor, A. M., Khalid, O., . . . Beumont, M. (2018). Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. Journal of Viral Hepatitis, 25(6), 631. https://doi.org/10.1111/jvh.12853

Chicago Style (17th ed.) Citation

Sulkowski, M. S., et al. "Efficacy and Safety of 6 or 8 Weeks of Simeprevir, Daclatasvir, Sofosbuvir for HCV Genotype 1 Infection." Journal of Viral Hepatitis 25, no. 6 (2018): 631. https://doi.org/10.1111/jvh.12853.

MLA (9th ed.) Citation

Sulkowski, M. S., et al. "Efficacy and Safety of 6 or 8 Weeks of Simeprevir, Daclatasvir, Sofosbuvir for HCV Genotype 1 Infection." Journal of Viral Hepatitis, vol. 25, no. 6, 2018, p. 631, https://doi.org/10.1111/jvh.12853.